Automate Your Wheel Strategy on PHVS
With Tiblio's Option Bot, you can configure your own wheel strategy including PHVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PHVS
- Rev/Share 0.0
- Book/Share 3.3707
- PB 5.9646
- Debt/Equity 0.0034
- CurrentRatio 8.3263
- ROIC -0.4441
- MktCap 1287826115.8252
- FreeCF/Share -2.5102
- PFCF -9.3811
- PE -6.5332
- Debt/Assets 0.003
- DivYield 0
- ROE -0.691
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PHVS | Guggenheim | -- | Buy | -- | $32 | June 11, 2025 |
| Initiation | PHVS | Cantor Fitzgerald | -- | Overweight | -- | $28 | April 29, 2025 |
News
Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations
Published: July 23, 2025 by: Seeking Alpha
Sentiment: Positive
Pharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials for hereditary angioedema patient populations. Key catalysts include RAPIDe-3 phase 3 topline data in Q4 2025 for on-demand HAE and CHAPTER-3 prophylaxis data expected in the second half of 2026. Deucrictibant's unique oral formulation and dual-use potential could capture significant market share in the $19.68B HAE market if trials are successful.
Read More
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, June 02, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the 14th C1-Inhibitor Deficiency and Angioedema Workshop.
Read More
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Workshop, to be held from May 29-June 1, 2025, in Budapest; the 2025 Eastern Allergy Conference (EAC), to be held from May 29-June 1, 2025, in Palm Beach, Fl.; and the European Academy of Allergy …
Read More
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema
Read More
About Pharvaris N.V. (PHVS)
- IPO Date 2021-02-05
- Website https://pharvaris.com
- Industry Biotechnology
- CEO Berndt Axel Edvard Modig CPA,
- Employees 108